CN102573853A - 使用肌醇三焦磷酸减少多药抗性的方法 - Google Patents

使用肌醇三焦磷酸减少多药抗性的方法 Download PDF

Info

Publication number
CN102573853A
CN102573853A CN2010800396808A CN201080039680A CN102573853A CN 102573853 A CN102573853 A CN 102573853A CN 2010800396808 A CN2010800396808 A CN 2010800396808A CN 201080039680 A CN201080039680 A CN 201080039680A CN 102573853 A CN102573853 A CN 102573853A
Authority
CN
China
Prior art keywords
itpp
chemotherapeutics
cisplatin
paclitaxel
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800396808A
Other languages
English (en)
Chinese (zh)
Inventor
Y.C.尼科劳
J-M.莱恩
C.基达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université de Strasbourg
NormOxys Inc
Original Assignee
Université de Strasbourg
NormOxys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université de Strasbourg, NormOxys Inc filed Critical Université de Strasbourg
Publication of CN102573853A publication Critical patent/CN102573853A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800396808A 2009-07-07 2010-07-07 使用肌醇三焦磷酸减少多药抗性的方法 Pending CN102573853A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22358309P 2009-07-07 2009-07-07
US61/223,583 2009-07-07
PCT/US2010/041250 WO2011005886A1 (en) 2009-07-07 2010-07-07 Method of reducing multi-drug resistance using inositol tripyrophosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310347286.6A Division CN103495170A (zh) 2009-07-07 2010-07-07 使用肌醇三焦磷酸减少多药抗性的方法

Publications (1)

Publication Number Publication Date
CN102573853A true CN102573853A (zh) 2012-07-11

Family

ID=43429524

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800396808A Pending CN102573853A (zh) 2009-07-07 2010-07-07 使用肌醇三焦磷酸减少多药抗性的方法
CN201310347286.6A Pending CN103495170A (zh) 2009-07-07 2010-07-07 使用肌醇三焦磷酸减少多药抗性的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310347286.6A Pending CN103495170A (zh) 2009-07-07 2010-07-07 使用肌醇三焦磷酸减少多药抗性的方法

Country Status (7)

Country Link
US (3) US20120003327A1 (cg-RX-API-DMAC7.html)
EP (1) EP2451459B1 (cg-RX-API-DMAC7.html)
JP (2) JP2012532879A (cg-RX-API-DMAC7.html)
CN (2) CN102573853A (cg-RX-API-DMAC7.html)
MX (1) MX2012000383A (cg-RX-API-DMAC7.html)
RU (1) RU2563127C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011005886A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358157A (zh) * 2013-03-14 2016-02-24 海加制药有限责任公司 饮品和其用途
CN110461311A (zh) * 2016-08-26 2019-11-15 奥野哲治 微细纳米化药剂及其应用
CN112074276A (zh) * 2018-05-03 2020-12-11 诺姆奥克塞斯公司 一种肌醇基免疫疗法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
WO2018067646A1 (en) * 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc Compounds and methods for activating tie2 signaling
US20200390723A1 (en) * 2017-12-22 2020-12-17 Lo.Li. Pharma International S.R.L. Treatment of fibrosis with inositol
TWI686210B (zh) 2018-06-01 2020-03-01 國立清華大學 用以誘導病變組織血管正常化的套組及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102060A1 (en) * 2005-03-18 2006-09-28 Oxyplus, Inc. Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
US6632797B2 (en) * 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
JP3989997B2 (ja) * 1997-04-08 2007-10-10 ポーラ化成工業株式会社 放射線増感剤の製造方法
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
DE60019622T2 (de) * 1999-09-13 2006-03-02 Pola Chemical Industries, Inc. Nitroimidazolderivate und diese enthaltende diagnostische bilderzeugungsmittel
WO2003092700A1 (en) * 2002-04-29 2003-11-13 Gmp Oxycell, Inc. Inositol pyrophosphates, and methods of use thereof
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CA2636089A1 (en) * 2006-01-06 2007-07-19 Oxyplus, Inc. Use of inositol-tripyrophosphate in treating tumors and diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102060A1 (en) * 2005-03-18 2006-09-28 Oxyplus, Inc. Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLAUDINE KIEDA等: "Suppression of hypoxia-induced HIF-1a and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358157A (zh) * 2013-03-14 2016-02-24 海加制药有限责任公司 饮品和其用途
CN110461311A (zh) * 2016-08-26 2019-11-15 奥野哲治 微细纳米化药剂及其应用
CN112074276A (zh) * 2018-05-03 2020-12-11 诺姆奥克塞斯公司 一种肌醇基免疫疗法

Also Published As

Publication number Publication date
US20160235771A1 (en) 2016-08-18
EP2451459A1 (en) 2012-05-16
WO2011005886A1 (en) 2011-01-13
CN103495170A (zh) 2014-01-08
US20140199261A1 (en) 2014-07-17
RU2563127C2 (ru) 2015-09-20
MX2012000383A (es) 2012-06-01
EP2451459B1 (en) 2017-11-22
JP2012532879A (ja) 2012-12-20
EP2451459A4 (en) 2013-12-11
RU2012104022A (ru) 2013-08-20
JP2015166393A (ja) 2015-09-24
US20120003327A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
Dong et al. Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy
Li et al. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy
Guo et al. Thrombin-responsive, brain-targeting nanoparticles for improved stroke therapy
US20160235771A1 (en) Method of reducing multi-drug resistance using inositol tripyrophosphate
CN104717966B (zh) 用于癌症靶向治疗和预防癌症复发的含有基于血红蛋白的氧载体的药物组合物
Shahzad et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles
Kinoh et al. Nanomedicines eradicating cancer stem-like cells in vivo by pH-triggered intracellular cooperative action of loaded drugs
Angara et al. Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies
RU2708332C2 (ru) Лечение лимфом
AU2008233550B2 (en) Targeting agent for cancer cell or cancer-associated fibroblast
Li et al. Co-delivery of metformin enhances the antimultidrug resistant tumor effect of doxorubicin by improving hypoxic tumor microenvironment
US20160074390A1 (en) Human dosing of phosphatase inhibitor
Feng et al. A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3
Shimizu et al. Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug
JP2025535140A (ja) ジベンゾオキサゼピノンを使用した、免疫細胞活性化を増大させる、および／またはがんを治療する方法
Liu et al. A “Depolarization‐Activation” Strategy Targeting Microglia: Cuproptosis‐Mediated Immune Re‐Sensitization Nanoplatform in Glioma Therapy
US20250352490A1 (en) P-selectin targeted nanoparticles and uses thereof
US20220409581A1 (en) Methods and compositions for treatment of solid tumors using f16 isoindole small molecules
Eren Cimenci Biomaterial Therapy Strategies for Treating the Infarcted Heart
Lai et al. Intravesical cascade delivery of active monoterpene coumarin for bladder cancer therapy
Hao et al. Precise co-delivery of drug and cytotoxic exosomes using a biomimetic nanorobot for glioma regression and recurrence prevention
Wu et al. A nano-system combines mitochondrial damage with microtubule stabilization for cancer metastasis suppression
JP2024113036A (ja) 医薬組成物及び組み合わせ物
KR20250000043A (ko) 나노입자, 이의 제조 방법 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
Prasad Nanotechnology-Based Strategies To Enhance Chemo-And Radiation Therapy In Breast Cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711